Ischemic Stroke

ORLANDO, Fla. — The COVID-19 pandemic likely altered stroke patient characteristics, as those admitted to the hospital were younger and had more severe symptoms over a 2-year post-pandemic interval, according to a poster.

Halting oral anticoagulation during transcatheter aortic valve replacement was not noninferior to anticoagulant continuation, but conferred lower bleeding risk and had no impact on thromboembolic risk, a speaker reported.

Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.

In those with acute ischemic stroke, endovascular thrombectomy was associated with better overall outcomes at 12 months compared with standard medical treatment alone, according to research from The Lancet Neurology.

Higher BMI during early adulthood was associated with an elevated risk for CV outcomes, like heart disease and stroke, among adults aged 35 to 70 years, according to a study published in The Lancet Public Health.

Use of radial access for PCI has increased greatly in the U.S. over the last decade and is associated with lower risk for mortality, bleeding and nonfatal vascular complications compared with a transfemoral approach, a speaker reported.

Use of advanced thrombolysis in the U.S. remains low and is prone to disparate use among women and Black patients presenting with pulmonary embolism, a speaker reported.

In a meta-analysis of studies covering more than 400,000 people, climbing stairs was associated with reduced risk for all-cause mortality and death from heart disease.

Patients with syphilis experienced higher rates of CV events like stroke, MI and death compared with a matched control group, according to a large-scale, real-world study published in European Heart Journal.

ATLANTA — In patients with ACS who underwent PCI, ticagrelor monotherapy after 1 month lowered bleeding risk by 55% compared with dual antiplatelet therapy for 12 months, according to the results of the ULTIMATE-DAPT trial.